Shorts On Watch: Could Cytokinetics (NASDAQ:CYTK) Skyrocket? The Stock Had Too Little Sellers

December 1, 2016 - By Adrian Mccoy   ·   0 Comments

Shorts On Watch: Could Cytokinetics (NASDAQ:CYTK) Skyrocket? The Stock Had Too Little Sellers

The stock of Cytokinetics (NASDAQ:CYTK) registered a decrease of 11.09% in short interest. CYTK’s total short interest was 3.11 million shares in December as published by FINRA. Its down 11.09% from 3.50 million shares, reported previously. With 336,800 shares average volume, it will take short sellers 9 days to cover their CYTK’s short positions. The short interest to Cytokinetics’s float is 11.91%. The stock decreased 2.83% or $0.35 during the last trading session, hitting $12. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 45.28% since April 28, 2016 and is uptrending. It has outperformed by 39.35% the S&P500.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has a market cap of $486.20 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It currently has negative earnings. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.70, from 0.46 in 2016Q1. The ratio improved, as 19 funds sold all Cytokinetics, Inc. shares owned while 37 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 26.30 million shares or 0.76% less from 26.50 million shares in 2016Q1.
Panagora Asset holds 0% or 76,805 shares in its portfolio. Wade G W & owns 20,000 shares or 0.03% of their US portfolio. Strs Ohio owns 64,900 shares or 0% of their US portfolio. Blackrock Institutional Na has invested 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK). Blackrock Japan accumulated 720 shares or 0% of the stock. Weiss Multi owns 13,122 shares or 0.01% of their US portfolio. Venbio Select Advisor Ltd Liability Company last reported 503,900 shares in the company. Springbok Mgmt Lc reported 1,500 shares or 0% of all its holdings. Sphera Funds Mgmt Limited has 0.08% invested in the company for 32,069 shares. Blackrock Fund Advsrs, a California-based fund reported 881,984 shares. Bnp Paribas Arbitrage Sa, a New York-based fund reported 1,317 shares. Blackrock Ltd accumulated 11,656 shares or 0% of the stock. Ladenburg Thalmann Fincl Svcs reported 2,045 shares or 0% of all its holdings. Blackrock Inv Ltd Liability Company owns 129,386 shares or 0% of their US portfolio. Bvf Il has 4.99 million shares for 10.09% of their US portfolio.

Cytokinetics, Inc. (NASDAQ:CYTK) Ratings Coverage

Out of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 6 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by TH Capital given on Monday, November 9. FBR Capital maintained Cytokinetics, Inc. (NASDAQ:CYTK) rating on Tuesday, November 10. FBR Capital has “Outperform” rating and $24 price target. The stock has “Buy” rating given by Roth Capital on Monday, November 9. Needham maintained Cytokinetics, Inc. (NASDAQ:CYTK) on Wednesday, July 27 with “Buy” rating. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. MLV maintained Cytokinetics, Inc. (NASDAQ:CYTK) rating on Friday, July 24. MLV has “Buy” rating and $14 price target.

CYTK Company Profile

Cytokinetics, Incorporated, incorporated on August 5, 1997, is a late-stage biopharmaceutical company. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Firm is developing small molecule drug candidates, which are specifically engineered to increase muscle function and contractility. The Company’s drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

More important recent Cytokinetics, Inc. (NASDAQ:CYTK) news were published by: Fool.com which released: “Why Cytokinetics, Inc. Got Hammered Today” on September 01, 2016, also Globenewswire.com published article titled: “Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results”, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on December 21, 2009. More interesting news about Cytokinetics, Inc. (NASDAQ:CYTK) was released by: Globenewswire.com and their article: “Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>